Neuronetics ( (STIM) ) just unveiled an update.
On March 4, 2025, Neuronetics announced its financial and operating results for the fourth quarter and full year of 2024, highlighting significant developments including the acquisition of Greenbrook TMS on December 9, 2024, and a revenue increase of 11% in the fourth quarter compared to the previous year. The company also reported a full-year revenue of $74.9 million, a 5% increase from 2023, and received FDA clearance for adolescent treatments. Neuronetics completed a secondary offering raising $18.9 million in February 2025 and executed actions to achieve $21 million in annualized cost synergies from the Greenbrook acquisition. Despite a decrease in gross margin due to the inclusion of Greenbrook’s clinic business, Neuronetics is positioned as a leader in TMS therapy, aiming for double-digit revenue growth and cash flow positivity by Q3 2025.
More about Neuronetics
Neuronetics, Inc. is a vertically integrated, commercial stage medical technology and healthcare company focused on neurohealth therapies. The company is known for its NeuroStar Advanced Therapy System, which is used for transcranial magnetic stimulation (TMS) treatments, and aims to transform patient lives with leading neurohealth therapies.
YTD Price Performance: 185.23%
Average Trading Volume: 1,195,398
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $170.3M
For detailed information about STIM stock, go to TipRanks’ Stock Analysis page.